DROP-TECH LTD

Their core work

Drop-Tech is a Cambridge-based SME specializing in droplet microfluidics technology — miniaturized systems that generate, manipulate, and sort millions of tiny liquid droplets for high-throughput biological screening. Their core business is providing microfluidic platforms and expertise that enable researchers to screen massive libraries of proteins, enzymes, and microbial variants far faster and cheaper than conventional methods. They serve as a technology provider to academic consortia working on directed evolution, metagenomics, and biocatalysis, supplying the hardware and know-how that turns lab-scale experiments into industrial-scale screening campaigns.

What they specialise in

How they've shifted over time

Drop-Tech's H2020 involvement spans 2016–2023 with a consistent thematic thread but a sharpening focus. Their earliest project (METAFLUIDICS, 2016) applied microfluidics broadly to metagenomic screening, while their later projects (ES-Cat, EVOdrops) narrowed specifically toward directed evolution and biocatalysis applications. The trajectory shows a company moving from general-purpose microfluidic screening toward becoming a go-to technology partner for enzyme and protein engineering research networks.

Drop-Tech is deepening its specialization in droplet-based directed evolution platforms, positioning itself as an essential technology partner for the growing European biocatalysis and synthetic biology community.

How they like to work

Drop-Tech operates almost exclusively as a third-party contributor or specialist participant — they have never coordinated an H2020 project. Their role in three out of four projects as a third party indicates they provide specific technology or services to consortia rather than driving the research agenda. Despite their small size, they have connected with 61 partners across 19 countries, suggesting they are a sought-after specialist that multiple research networks pull in for their microfluidics capabilities.

Despite being a small SME, Drop-Tech has built a surprisingly broad network of 61 consortium partners across 19 countries, primarily through MSCA training networks. Their reach spans most of Europe, reflecting the wide demand for their specialized microfluidics technology across multiple research groups.

What sets them apart

Drop-Tech occupies a very specific niche: they are one of few commercial providers of droplet microfluidics platforms purpose-built for directed evolution and high-throughput biological screening. Their Cambridge base places them at the heart of the UK's biotech ecosystem, and their repeated inclusion as a third party in MSCA training networks shows that top European research groups trust their technology enough to build PhD training around it. For consortium builders, they offer a rare combination — commercial microfluidics hardware expertise paired with deep understanding of biological screening applications.

Highlights from their portfolio

• METAFLUIDICS
  Their only directly-funded project (EUR 207,820), combining microfluidics with metagenomics for functional screening — the project that likely established their EU research network.
• EVOdrops
  Most recent and longest-running project (2018-2023), directly aligned with their core brand — directed evolution in droplets — suggesting this is where their technology is heading.
• ES-Cat
  Part of an MSCA training network on directed protein evolution for synthetic biology and biocatalysis, connecting them to the next generation of researchers in their field.